Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder

Jan Volavka, Thomas B. Cooper, P. Czobor, Morris Meisner

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Double-blind haloperidol was administered during two consecutive 3-week periods to 65 patients with acutely exacerbating schizophrenia or schizoaffective disorder. Two plasma levels were targeted: low (2 ng/mL) and moderate (10 ng/mL). The subjects were randomly assigned to four treatment sequences (low-low, low-moderate, moderate-moderate, or moderate-low). Data from 28 patients were available for the analyses of the second study period. In that period, decrease of plasma levels reduced mild but not severe negative symptoms. Thus, towering of the plasma levels after the first 3 weeks of treatment may improve mild negative symptoms. Conversely, increasing the plasma levels may make mild negative symptoms worse.

Original languageEnglish
Pages (from-to)75-79
Number of pages5
JournalPsychopharmacology Bulletin
Volume32
Issue number1
Publication statusPublished - 1996

Fingerprint

Haloperidol
Psychotic Disorders
Schizophrenia
Therapeutics

Keywords

  • haloperidol
  • negative symptoms
  • plasma level
  • schizoaffective disorder
  • schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder. / Volavka, Jan; Cooper, Thomas B.; Czobor, P.; Meisner, Morris.

In: Psychopharmacology Bulletin, Vol. 32, No. 1, 1996, p. 75-79.

Research output: Contribution to journalArticle

@article{ee224d1c073447e0aae8a913151904e3,
title = "Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder",
abstract = "Double-blind haloperidol was administered during two consecutive 3-week periods to 65 patients with acutely exacerbating schizophrenia or schizoaffective disorder. Two plasma levels were targeted: low (2 ng/mL) and moderate (10 ng/mL). The subjects were randomly assigned to four treatment sequences (low-low, low-moderate, moderate-moderate, or moderate-low). Data from 28 patients were available for the analyses of the second study period. In that period, decrease of plasma levels reduced mild but not severe negative symptoms. Thus, towering of the plasma levels after the first 3 weeks of treatment may improve mild negative symptoms. Conversely, increasing the plasma levels may make mild negative symptoms worse.",
keywords = "haloperidol, negative symptoms, plasma level, schizoaffective disorder, schizophrenia",
author = "Jan Volavka and Cooper, {Thomas B.} and P. Czobor and Morris Meisner",
year = "1996",
language = "English",
volume = "32",
pages = "75--79",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "1",

}

TY - JOUR

T1 - Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder

AU - Volavka, Jan

AU - Cooper, Thomas B.

AU - Czobor, P.

AU - Meisner, Morris

PY - 1996

Y1 - 1996

N2 - Double-blind haloperidol was administered during two consecutive 3-week periods to 65 patients with acutely exacerbating schizophrenia or schizoaffective disorder. Two plasma levels were targeted: low (2 ng/mL) and moderate (10 ng/mL). The subjects were randomly assigned to four treatment sequences (low-low, low-moderate, moderate-moderate, or moderate-low). Data from 28 patients were available for the analyses of the second study period. In that period, decrease of plasma levels reduced mild but not severe negative symptoms. Thus, towering of the plasma levels after the first 3 weeks of treatment may improve mild negative symptoms. Conversely, increasing the plasma levels may make mild negative symptoms worse.

AB - Double-blind haloperidol was administered during two consecutive 3-week periods to 65 patients with acutely exacerbating schizophrenia or schizoaffective disorder. Two plasma levels were targeted: low (2 ng/mL) and moderate (10 ng/mL). The subjects were randomly assigned to four treatment sequences (low-low, low-moderate, moderate-moderate, or moderate-low). Data from 28 patients were available for the analyses of the second study period. In that period, decrease of plasma levels reduced mild but not severe negative symptoms. Thus, towering of the plasma levels after the first 3 weeks of treatment may improve mild negative symptoms. Conversely, increasing the plasma levels may make mild negative symptoms worse.

KW - haloperidol

KW - negative symptoms

KW - plasma level

KW - schizoaffective disorder

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0029990611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029990611&partnerID=8YFLogxK

M3 - Article

C2 - 8927679

AN - SCOPUS:0029990611

VL - 32

SP - 75

EP - 79

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 1

ER -